We have updated our Psychedelic Company Financing Tracker to reflect activity in Q2 2024. You can explore the interactive charts here. As a reminder, Q1 2024 got off to a roaring start, with a small crop of substantial rounds such as Lykos Therapeutics’ $100m+ Series A as well as both Cybin and MindMed’s significant public offerings. To be sure, valuations for these rounds were markedly more…
